Sharechat Logo

Metlifecare says annual earnings may rise as much as 43%

Friday 23rd May 2014

Text too small?

 

Metlifecare, the retirement village operator which counts the New Zealand Superannuation Fund and Infratil as cornerstone investors, raised its guidance for full-year earnings, saying underlying profit may rise as much as 43 percent as it benefits from higher sales, bigger capital gains on property sales and more income from resales.

 

 

Underlying profit will probably be $43 million to $46 million in the year ending June 30, up from its previous expectation of $34 million to $38 million, and from $32.1 million a year earlier, the Auckland-based company said in a statement. The guidance assumes recent trading conditions continue over the last two months of the financial year, it said. Underlying profit removes one-off gains, unrealised movements in the value of the company's property portfolio and deferred tax.

 

 

Metlifecare reported a 77 percent lift in first-half underlying profit to $15.3 million, and is focused on driving development opportunities in the upper North Island, where it hopes to benefit from an ageing population in need of quality retirement and aged care facilities. Today's upgrade to earnings guidance reflects stronger settlements activity at The Poynton Stage 3 development, higher capital gains and deferred membership fee income from resales activity, the company said.

 

 

The shares last traded at $4.18, and have gained 5.6 percent so far this year.

 

 

 

 

BusinessDesk.co.nz



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors